contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


offentliggorelse-af-forventet-kapitalforhojelse

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Equity Research Assistant

Victor Skriver

Scape Technologies is a Danish automation and software company specialized in Bin-Picking robotics based on 3D computer systems. SCAPE Bin-Picker systems automate and replace manual jobs by handling small components more efficiently. Scape Technologies has a solid presence in the automotive industry with large customers, and Scape Technologies also has a large part of its sales in China.

Scape Technologies was founded in 2004, the company has been listed at Nasdaq First North in Denmark since November 2018.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Scape Technologies er en dansk automations- og softwarevirksomhed med speciale i Bin-Picking indenfor robotindustrien baseret på 3D-computersystemer. SCAPE Bin-Picker-systemer automatiserer og erstatter manuelle opgaver ved at håndtere små komponenter mere effektivt. Scape Technologies har en solid tilstedeværelse i bilindustrien med store kunder, og Scape Technologies har også en stor andel af salget i Kina. Scape Technologies blev grundlagt i 2004, virksomheden har været børsnoteret på Nasdaq First North i Danmark siden november 2018. English:  Scape Technologies is a Danish automation and software company specializing in Bin-Picking robotics based on 3D computer systems. SCAPE Bin-Picker systems automate and replace manual jobs by handling small components more efficiently. Scape Technologies has a solid presence in the automotive industry with large customers, and Scape Technologies also has a large part of its sales in China. Scape Technologies was founded in 2004, the company has been listed at Nasdaq First North in Denmark since November 2018.

Scape Technologies

Scape Technologies A/S har i dag offentliggjort planer om en forventet kapitalforhøjelse på DKK 18,5 millioner fra Shenzhen Scape Technologies (Scape China) gennem udstedelse af nye aktier mod kontant indbetaling. Der er hermed tale om en rettet emission...

<a href="https://www.linkedin.com/company/scape-technologies-a-s/">Scape Technologies A/S</a>&nbsp;har i dag offentliggjort planer om en forventet kapitalforhøjelse på DKK 18,5 millioner fra Shenzhen Scape Technologies (Scape China) gennem udstedelse af nye aktier mod kontant indbetaling.

Der er hermed tale om en rettet emission af 8 millioner aktier til markedskurs fastsat til DKK 2,32 per aktie. Kapitalforhøjelsen skal godkendes på den kommende ordinære generalforsamling, og forhøjelsen ventes først at blive gennemført i perioden mellem 1. maj 2022 og 30. september 2022.

På nuværende tidspunkt ejer Scape Technologies 17,4% af Scape China, der er et joint-venture mellem Scape Technologies og selskabets kinesiske hovedaktionær. I forbindelse med kapitaludvidelsen forventer Scape Technologies at sælge aktierne i Scape China for ca. DKK 3,1 millioner, som skal benyttes til investering i Scape Chinas samarbejdspartnere i Kina eller et nyt joint-venture selskab. Det fremgår, at forhandlinger pågår om dette.

I forlængelse af den forventede kapitaludvidelse foretager Scape Technologies’ kinesiske aktionærer en omstrukturering i ejerforholdene, hvor alle aktier overdrages ind i Scape China. Aktierne forventes overdraget den 30. april 2022. Efter den forventede kapitalforhøjelse og omstruktureringen af ejerforholdene forventes Scape China - som dermed ventes at blive ejet fuldt ud af kinesiske aktionærer - at have en samlet ejerandel på 51% af Scape Technologies.

Den nye kapital skal benyttes til eksekvering af vækst- og internationaliseringsstrategien, øgede investeringer i forskning og produktudvikling samt udvikling af distributionskanaler til skalering.

Link til meddelelsen: <a href="https://lnkd.in/eiKCkSFu">https://view.news.eu.nasdaq.com/view?id=b83831c1e91de7fb12a5123c8ef9d61bb&amp;lang=da</a>

HC Andersen Capital modtager betaling fra Scape Technologies for en Digital IR/Corporate Visibility abonnementsaftale. /<a href="https://www.linkedin.com/in/ACoAABQT-A4BnRs1p3vXorqhpeozxfjxO_2qp7Q">Kasper Lihn</a>&nbsp;kl. 13:38 d. 24-03-2022.

HC Andersen Capital

Offentliggørelse Af Forventet Kapitalforhøjelse

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

Helsinki Stock Exchange is cheap

Valuation methods: Valuation multiples

Stay up to date with our newsletter